Evidence map›Paper›PMID 30312839›Full record

Trial reportJournal of affective disorders2019

Disentangling the association of depression on the anti-fatigue effects of ketamine.

Leorey N Saligan, Cristan Farmer, Elizabeth D Ballard, Bashkim Kadriu, Carlos A Zarate

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of affective disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06064162 (A Pilot Study of Intravenous, Subanesthetic Dose of Ketamine Versus Placebo, A Crossover Design, for Multiple Sclerosis Related Fatigue), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06064162 early_phase1completednot on this mapstarted 2023, after this paper: background citation

A Pilot Study of Intravenous, Subanesthetic Dose of Ketamine Versus Placebo, A Crossover Design, for Multiple Sclerosis Related Fatigue

TypeinterventionalSponsorAlta Bates Summit Medical CenterRan2023 to 2025Enrolled21ConditionsMultiple SclerosisArmsketamine
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Leorey N SaliganDivision of Intramural Research, National Institute of Nursing Research, National Institutes of Health (NIH), Bethesda, MD USA. Electronic address: saliganl@mail.nih.gov.
Cristan FarmerExperimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, NIH, Bethesda, MD, USA.
Elizabeth D BallardExperimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, NIH, Bethesda, MD, USA.
Bashkim KadriuExperimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, NIH, Bethesda, MD, USA.
Carlos A ZarateExperimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, NIH, Bethesda, MD, USA.
National Institute of Mental Health · USNational Institute of Nursing Research · US

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Intramural NIH HHS Z99 NR999999
6 · The paper itself

Abstract

backgroundFatigue and depression are closely associated. The purpose of this secondary analysis was to understand the relationships between depression and improvements in specific depression domains on the anti-fatigue effects of ketamine, which we previously reported.

methodsThis secondary analysis re-evaluated data collected longitudinally from 39 patients with treatment-resistant Major Depressive Disorder (MDD) enrolled in a double-blind, randomized, placebo-controlled, crossover trial using a single intravenous infusion of ketamine hydrochloride (0.5 mg/kg over 40 minutes) or placebo. A mediation model assessed the effect of depression on the anti-fatigue effects of a single dose of intravenous ketamine versus placebo at Day 1 post-infusion. Fatigue was measured using the National Institutes of Health-Brief Fatigue Inventory (NIH-BFI), and depression was assessed by the Montgomery-Ǻsberg Depression Rating Scale (MADRS).

resultsCompared to placebo, ketamine significantly improved fatigue (p = .0003) as measured by the NIH-BFI, but the anti-fatigue effects of ketamine disappeared (p = .47) when controlling for depression as measured by MADRS total score. In this study sample, the anti-fatigue effects of ketamine were mostly accounted for by the changes in amotivation and depressed mood scores.

conclusionsIn this study, ketamine did not have a unique effect on fatigue outside of its general antidepressant effects in patients with treatment-resistant depression. Specifically, the anti-fatigue effects of ketamine observed in this study seem to be explained by the effects of ketamine on two symptom domains of depression: amotivation and depressed mood. The study findings suggest that the anti-fatigue effects of ketamine should be assessed by fatigue-specific measures other than the NIH-BFI or future studies should enroll fatigued patients without depression.

Indexed as

AdultAntidepressive AgentsCross-Over StudiesDepressive Disorder, Treatment-ResistantDouble-Blind MethodExcitatory Amino Acid AntagonistsFatigueFemaleHumansInfusions, IntravenousKetamineMajor Depressive DisorderMaleMiddle AgedPsychiatric Status Rating ScalesAntidepressive AgentsExcitatory Amino Acid AntagonistsKetamine

Identifiers

PMID30312839
PMCPMC6226316
OpenAlexW2895262293

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.